Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review

Executive Summary

Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application
Advertisement

Related Content

Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy
Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy
Generics Infringe On Branded Stock Growth As Investors Eye Mergers, Part D
FDA Takes More Conservative Approach To Quantifying Oncologic Benefit
FDA Takes More Conservative Approach To Quantifying Oncologic Benefit
Abbott Xinlay Review By Oncologic Committee Expected In Mid-September
Abbott Xinlay Review By Oncologic Committee Expected In Mid-September
Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July

Topics

Advertisement
UsernamePublicRestriction

Register

PS046318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel